Edition:
India

Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

181.22USD
16 Jul 2018
Change (% chg)

-- (--)
Prev Close
$181.22
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
576,710
52-wk High
$182.40
52-wk Low
$127.68

Latest Key Developments (Source: Significant Developments)

CRISPR And Vertex Provide Update On FDA Review Of Investigational NDA
Thursday, 31 May 2018 

May 30 (Reuters) - CRISPR Therapeutics AG ::CRISPR THERAPEUTICS AND VERTEX PROVIDE UPDATE ON FDA REVIEW OF INVESTIGATIONAL NEW DRUG APPLICATION FOR CTX001 FOR THE TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS-PLANNED INITIATION OF PHASE 1/2 TRIAL OF CTX001 IN EUROPE IN ADULT PATIENTS WITH TRANSFUSION DEPENDENT Β-THALASSEMIA IS UNCHANGED.CRISPR THERAPEUTICS AG - U.S FDA HAS PLACED A CLINICAL HOLD ON IND FOR CTX001 FOR TREATMENT OF SICKLE CELL DISEASE.CRISPR THERAPEUTICS AG - COMPANIES EXPECT TO INITIATE PHASE 1/2 TRIAL OF CTX001 IN SECOND HALF OF 2018.  Full Article

Vertex, CRISPR Therapeutics To Co-Develop CTX001 As CRISPR/Cas9 Gene Edited Treatment
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX AND CRISPR THERAPEUTICS TO CO-DEVELOP AND CO-COMMERCIALIZE CTX001 AS CRISPR/CAS9 GENE EDITED TREATMENT FOR SICKLE CELL DISEASE AND Β-THALASSEMIA.VERTEX PHARMACEUTICALS INC - VERTEX SELECTS CTX001 AS FIRST GENE EDITED TREATMENT TO BE DEVELOPED AS PART OF COLLABORATION WITH CRISPR THERAPEUTICS.VERTEX PHARMACEUTICALS - TRIAL APPLICATION FOR CTX001 SUBMITTED IN EUROPE TO SUPPORT INITIATION OF PHASE 1/2 CLINICAL STUDY IN Β-THALASSEMIA IN 2018.VERTEX PHARMACEUTICALS - IND APPLICATION PLANNED FOR SUBMISSION IN 2018 TO SUPPORT INITIATION OF A PHASE 1/2 TRIAL IN SICKLE CELL DISEASE FOR CTX001.  Full Article

Vertex Announces Positive Results From Open-Label Phase 3 Study Of KALYDECO(ivacaftor)
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Vertex Pharmaceuticals Inc ::VERTEX ANNOUNCES POSITIVE RESULTS FROM OPEN-LABEL PHASE 3 STUDY OF KALYDECO® (IVACAFTOR) IN CHILDREN WITH CYSTIC FIBROSIS AGES 1 TO 2 YEARS.VERTEX PHARMACEUTICALS - KALYDECO​ ‍STUDY MET PRIMARY SAFETY ENDPOINT, SHOWED IMPROVEMENTS ACROSS MULTIPLE ENDPOINTS.VERTEX PHARMACEUTICALS - ‍ARRIVAL STUDY GENERALLY WELL TOLERATED, SAFETY DATA WERE CONSISTENT WITH THOSE SEEN IN PREVIOUS PHASE 3 STUDIES OF IVACAFTOR​.VERTEX PHARMACEUTICALS INC - ‍VERTEX PLANS TO SUBMIT APPLICATIONS FOR IVACAFTOR TO FDA AND EMA IN Q1 OF 2018​.  Full Article

Vertex reports Q3 non-GAAP earnings per share $0.53
Thursday, 26 Oct 2017 

Oct 25 (Reuters) - Vertex Pharmaceuticals Inc :Vertex reports third-quarter 2017 financial results.Q3 non-GAAP earnings per share $0.53.Q3 GAAP loss per share $0.41.Q3 earnings per share view $0.31 -- Thomson Reuters I/B/E/S.Vertex Pharmaceuticals Inc says ‍third-quarter 2017 cystic fibrosis product revenues of $550 million, up 34% versus Q3 2016​.Says ‍increased its total 2017 CF product revenue guidance, including ORKAMBI and KALYDECO revenue guidance​.Vertex Pharmaceuticals Inc qtrly ‍product revenues for ORKAMBI $336 million and $213 million for KALYDECO​.Says ‍reiterated its 2017 combined GAAP and non-GAAP research and development and SG&A expense guidance​.Says ‍now expects total 2017 CF product revenues of $2.10 to $2.15 billion​.Vertex Pharmaceuticals Inc ‍increases FY ORKAMBI revenue guidance to $1.29 to $1.32 billion and KALYDECO revenue guidance to $810 to $830 million​.  Full Article

Vertex Pharmaceuticals says FTC requested for additional information on pending acquisition from Concert Pharmaceuticals
Monday, 22 May 2017 

May 22 (Reuters) - Concert Pharmaceuticals Inc :Vertex Pharmaceuticals says on May 19, the U.S. FTC issued a request for additional information in connection co's pending acquisition of CTP-656 and other assets from Concert Pharmaceuticals.The second request was issued under notification requirements of the Hart-Scott-Rodino antitrust improvements act.Vertex Pharmaceuticals says it intends to work cooperatively with the FTC as it reviews the transaction.  Full Article

Vertex Pharma: Amended and expanded agreement with Cystic Fibrosis Foundation Therapeutics
Friday, 14 Oct 2016 

Vertex Pharmaceuticals Inc : Vertex Pharma - on oct 13 amended and expanded research, development and commercialization agreement with cystic fibrosis foundation therapeutics inc . Vertex Pharma - amendment provides for upfront program award from cfft to us of $75.0 million,development funding from cfft to us of upto $6.0 million annually . Vertex Pharmaceuticals Inc- pursuant to amendment , co will continue to pay royalties ranging from low single digits to mid-single digits .Vertex Pharma-entered into data license deal with Cystic Fibrosis Foundation, co will pay for continuing access to data from CFF's patient registry.  Full Article

Vertex enrollment complete in Phase 3 study in people with two copies of F508DEL mutation
Tuesday, 16 Aug 2016 

Vertex : Provides update on ongoing phase 3 program For VX-661 in combination with ivacaftor for the treatment of cystic fibrosis . Enrollment complete in phase 3 study in people with two copies of F508DEL mutation . Enrollment expected to be completed in September in phase 3 study in people with one F508DEL mutation, one residual function mutation .Plans to submit new drug application (NDA) to FDA for vx-661 in combination with ivacaftor in second half of 2017.  Full Article

Vertex Pharmaceuticals says reiterates 2016 guidance
Thursday, 28 Jul 2016 

Vertex Pharmaceuticals Inc : Vertex pharmaceuticals inc says reiterates 2016 guidance for orkambi product revenues of $1.0 to $1.1 billion . Gaap research and development and sg&a expenses . Vertex reports second quarter 2016 financial results . Q2 non-gaap earnings per share $0.24 . Q2 gaap loss per share $0.26 . Q2 earnings per share view $0.21 -- Thomson Reuters I/B/E/S .Vertex pharmaceuticals inc says reiterates 2016 guidance for kalydeco product revenues of $685 to $705 million.  Full Article

Vertex Pharma profit tops estimates on strong launch of new CF drug

Vertex Pharmaceuticals Inc topped analysts' forecasts for quarterly profit on Thursday, led by stronger-than expected sales of its latest cystic fibrosis drug as well as double-digit growth in sales of older treatments.